Type 2 diabetes remission: 2 year within-trial and lifetime-horizon cost-effectiveness of the Diabetes Remission Clinical Trial (DiRECT)/Counterweight-Plus weight management programme

AIMS/HYPOTHESIS: Approximately 10% of total healthcare budgets worldwide are spent on treating diabetes and its complications, and budgets are increasing globally because of ageing populations and more expensive second-line medications. The aims of the study were to estimate the within-trial and lif...

Descripción completa

Detalles Bibliográficos
Autores principales: Xin, Yiqiao, Davies, Andrew, Briggs, Andrew, McCombie, Louise, Messow, C. Martina, Grieve, Eleanor, Leslie, Wilma S., Taylor, Roy, Lean, Michael E. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476973/
https://www.ncbi.nlm.nih.gov/pubmed/32776237
http://dx.doi.org/10.1007/s00125-020-05224-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476973/
https://www.ncbi.nlm.nih.gov/pubmed/32776237
http://dx.doi.org/10.1007/s00125-020-05224-2

Ejemplares similares